Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot.

Mateo M, Reynard S, Carnec X, Journeaux A, Baillet N, Schaeffer J, Picard C, Legras-Lachuer C, Allan R, Perthame E, Hillion KH, Pietrosemoli N, Dillies MA, Barrot L, Vallve A, Barron S, Fellmann L, Gaillard JC, Armengaud J, Carbonnelle C, Raoul H, Tangy F, Baize S.

Sci Transl Med. 2019 Oct 2;11(512). pii: eaaw3163. doi: 10.1126/scitranslmed.aaw3163.

PMID:
31578242
2.

[Lassa virus and myeloid dendritic cells: a privileged tropism for the suppression of the T lymphocyte response].

Baize S.

Med Sci (Paris). 2019 Aug-Sep;35(8-9):619-621. doi: 10.1051/medsci/2019122. Epub 2019 Sep 18. French. No abstract available.

PMID:
31532370
3.

Fatal Case of Lassa Fever, Bangolo District, Côte d'Ivoire, 2015.

Mateo M, Picard C, Sylla Y, Kamo E, Odegue D, Journeaux A, Kan SK, Money M, Coulibaly DN, Koffi E, Meite S, Akran V, Kadjo H, Adjogoua E, Kakou SN, Baize S, Dosso M.

Emerg Infect Dis. 2019 Sep;25(9):1753-1756. doi: 10.3201/eid2509.190239.

4.

Autophagy Promotes Infectious Particle Production of Mopeia and Lassa Viruses.

Baillet N, Krieger S, Journeaux A, Caro V, Tangy F, Vidalain PO, Baize S.

Viruses. 2019 Mar 23;11(3). pii: E293. doi: 10.3390/v11030293.

5.

Non-Pathogenic Mopeia Virus Induces More Robust Activation of Plasmacytoid Dendritic Cells than Lassa Virus.

Schaeffer J, Reynard S, Carnec X, Pietrosemoli N, Dillies MA, Baize S.

Viruses. 2019 Mar 21;11(3). pii: E287. doi: 10.3390/v11030287.

6.

Immune parameters and outcomes during Ebola virus disease.

Reynard S, Journeaux A, Gloaguen E, Schaeffer J, Varet H, Pietrosemoli N, Mateo M, Baillet N, Laouenan C, Raoul H, Mullaert J, Baize S.

JCI Insight. 2019 Jan 10;4(1). pii: 125106. doi: 10.1172/jci.insight.125106. [Epub ahead of print]

7.

Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells.

Schaeffer J, Carnec X, Reynard S, Mateo M, Picard C, Pietrosemoli N, Dillies MA, Baize S.

PLoS Pathog. 2018 Nov 12;14(11):e1007430. doi: 10.1371/journal.ppat.1007430. eCollection 2018 Nov.

8.

Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.

Madelain V, Baize S, Jacquot F, Reynard S, Fizet A, Barron S, Solas C, Lacarelle B, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X, Guedj J.

Nat Commun. 2018 Oct 1;9(1):4013. doi: 10.1038/s41467-018-06215-z.

9.

A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.

Carnec X, Mateo M, Page A, Reynard S, Hortion J, Picard C, Yekwa E, Barrot L, Barron S, Vallve A, Raoul H, Carbonnelle C, Ferron F, Baize S.

J Virol. 2018 May 29;92(12). pii: e02230-17. doi: 10.1128/JVI.02230-17. Print 2018 Jun 15.

10.

Strengthened Ebola surveillance in France during a major outbreak in West Africa: March 2014-January 2016.

Mailles A, Noel H, Pannetier D, Rapp C, Yazdanpanah Y, Vandentorren S, Chaud P, Philippe JM, Worms B, Bruyand M, Tourdjman M, Nahon M, Belchior E, Lucas E, Durand J, Zurbaran M, Vaux S, Coignard B, DE Valk H, Baize S, Quelet S, Bourdillon F.

Epidemiol Infect. 2017 Dec;145(16):3455-3467. doi: 10.1017/S0950268817002552. Epub 2017 Nov 23.

PMID:
29168445
11.

Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs.

Tartour K, Nguyen XN, Appourchaux R, Assil S, Barateau V, Bloyet LM, Burlaud Gaillard J, Confort MP, Escudero-Perez B, Gruffat H, Hong SS, Moroso M, Reynard O, Reynard S, Decembre E, Ftaich N, Rossi A, Wu N, Arnaud F, Baize S, Dreux M, Gerlier D, Paranhos-Baccala G, Volchkov V, Roingeard P, Cimarelli A.

PLoS Pathog. 2017 Sep 28;13(9):e1006610. doi: 10.1371/journal.ppat.1006610. eCollection 2017 Sep.

12.

Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea.

Vernet MA, Reynard S, Fizet A, Schaeffer J, Pannetier D, Guedj J, Rives M, Georges N, Garcia-Bonnet N, Sylla AI, Grovogui P, Kerherve JY, Savio C, Savio-Coste S, de Séverac ML, Zloczewski P, Linares S, Harouna S, Abdoul BM, Petitjean F, Samake N, Shepherd S, Kinda M, Koundouno FR, Joxe L, Mateo M, Lecine P, Page A, Tchamdja TM, Schoenhals M, Barbe S, Simon B, Tran-Minh T, Longuet C, L'Hériteau F, Baize S.

JCI Insight. 2017 Mar 23;2(6):e88864. doi: 10.1172/jci.insight.88864.

13.

Dynamics of Ebola RNA Persistence in Semen: A Report From the Postebogui Cohort in Guinea.

Subtil F, Delaunay C, Keita AK, Sow MS, Touré A, Leroy S, Msellati P, Magassouba N, Baize S, Raoul H, Ecochard R, Barry M, Delaporte E, Etard JF; Postebogui Study Group.

Clin Infect Dis. 2017 Jun 15;64(12):1788-1790. doi: 10.1093/cid/cix210.

PMID:
28329169
14.

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.

Nguyen TH, Guedj J, Anglaret X, Laouénan C, Madelain V, Taburet AM, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentré F; JIKI study group.

PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389. doi: 10.1371/journal.pntd.0005389. eCollection 2017 Feb.

15.

Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study.

Etard JF, Sow MS, Leroy S, Touré A, Taverne B, Keita AK, Msellati P, Magassouba N, Baize S, Raoul H, Izard S, Kpamou C, March L, Savane I, Barry M, Delaporte E; Postebogui Study Group.

Lancet Infect Dis. 2017 May;17(5):545-552. doi: 10.1016/S1473-3099(16)30516-3. Epub 2017 Jan 14.

PMID:
28094208
16.

Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies.

van Griensven J, Edwards T, Baize S; Ebola-Tx Consortium.

N Engl J Med. 2016 Dec 8;375(23):2307-2309. doi: 10.1056/NEJMc1609116. Epub 2016 Nov 14. No abstract available.

17.

New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors.

Sow MS, Etard JF, Baize S, Magassouba N, Faye O, Msellati P, Touré A 2nd, Savane I, Barry M, Delaporte E; Postebogui Study Group.

J Infect Dis. 2016 Nov 15;214(10):1475-1476. Epub 2016 May 3.

PMID:
27142204
18.

Present-day uplift of the western Alps.

Nocquet JM, Sue C, Walpersdorf A, Tran T, Lenôtre N, Vernant P, Cushing M, Jouanne F, Masson F, Baize S, Chéry J, van der Beek PA.

Sci Rep. 2016 Jun 27;6:28404. doi: 10.1038/srep28404.

19.

Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Munoz VC, Doumbouya L, Harouna S, Kighoma PM, Koundouno FR, Lolamou R, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Uwamahoro MG, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, de Sainte Fare EB, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Duverger TA, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D; JIKI Study Group.

PLoS Med. 2016 Apr 5;13(4):e1002009. doi: 10.1371/journal.pmed.1002009. eCollection 2016 Apr.

20.

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea.

Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley Harouna, Kighoma PM, Koundouno FR, Réné Lolamou, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C, Soumah A, Arnould I, Komano MS, Gustin L, Berutto C, Camara D, Camara FS, Colpaert J, Delamou L, Jansson L, Kourouma E, Loua M, Malme K, Manfrin E, Maomou A, Milinouno A, Ombelet S, Sidiboun AY, Verreckt I, Yombouno P, Bocquin A, Carbonnelle C, Carmoi T, Frange P, Mely S, Nguyen VK, Pannetier D, Taburet AM, Treluyer JM, Kolie J, Moh R, Gonzalez MC, Kuisma E, Liedigk B, Ngabo D, Rudolf M, Thom R, Kerber R, Gabriel M, Di Caro A, Wölfel R, Badir J, Bentahir M, Deccache Y, Dumont C, Durant JF, El Bakkouri K, Gasasira Uwamahoro M, Smits B, Toufik N, Van Cauwenberghe S, Ezzedine K, D'Ortenzio E, Pizarro L, Etienne A, Guedj J, Fizet A, Barte de Sainte Fare E, Murgue B, Tran-Minh T, Rapp C, Piguet P, Poncin M, Draguez B, Allaford Duverger T, Barbe S, Baret G, Defourny I, Carroll M, Raoul H, Augier A, Eholie SP, Yazdanpanah Y, Levy-Marchal C, Antierrens A, Van Herp M, Günther S, de Lamballerie X, Keïta S, Mentre F, Anglaret X, Malvy D; JIKI Study Group.

PLoS Med. 2016 Mar 1;13(3):e1001967. doi: 10.1371/journal.pmed.1001967. eCollection 2016 Mar. Erratum in: PLoS Med. 2016 Apr;13(4):e1002009. Dortenzio, Eric [corrected to D’Ortenzio, Eric]. PLoS Med. 2016 Jun;13(6):e1002066.

21.

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea.

van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, Horby PW, Raoul H, Magassouba N, Antierens A, Lomas C, Faye O, Sall AA, Fransen K, Buyze J, Ravinetto R, Tiberghien P, Claeys Y, De Crop M, Lynen L, Bah EI, Smith PG, Delamou A, De Weggheleire A, Haba N; Ebola-Tx Consortium.

N Engl J Med. 2016 Jan 7;374(1):33-42. doi: 10.1056/NEJMoa1511812.

22.

[Viral zoonoses and emergence: research is just starting].

Salvetti A, Baize S.

Med Sci (Paris). 2015 Dec;31(12):1055-6. doi: 10.1051/medsci/20153112001. Epub 2015 Dec 16. French. No abstract available.

23.

Towards deep insight into Ebola virus disease.

Baize S.

Lancet Infect Dis. 2015 Sep;15(9):991-992. doi: 10.1016/S1473-3099(15)00058-4. Epub 2015 Jul 19. No abstract available.

PMID:
26201297
24.

Severe Ebola Virus Infection With Encephalopathy: Evidence for Direct Virus Involvement.

Sagui E, Janvier F, Baize S, Foissaud V, Koulibaly F, Savini H, Maugey N, Aletti M, Granier H, Carmoi T.

Clin Infect Dis. 2015 Nov 15;61(10):1627-8. doi: 10.1093/cid/civ606. Epub 2015 Jul 21. No abstract available.

PMID:
26197842
25.

Identification of essential outstanding questions for an adequate European laboratory response to Ebolavirus Zaire West Africa 2014.

Reusken C, Niedrig M, Pas S, Anda P, Baize S, Charrel R, Di Caro A, Drosten C, Fernandez-Garcia MD, Franco L, Gunther S, Leparc-Goffart I, Martina B, Pannetier D, Papa A, Sanchez-Seco MP, Vapalahti O, Koopmans M.

J Clin Virol. 2015 Jan;62:124-34.

PMID:
25692204
26.

Ebola virus in West Africa: new conquered territories and new risks-or how I learned to stop worrying and (not) love Ebola virus.

Baize S.

Curr Opin Virol. 2015 Feb;10:70-6. doi: 10.1016/j.coviro.2015.01.008. Epub 2015 Feb 6. Review.

PMID:
25666186
27.

Ebola: should we consider influenza vaccination?

Matheron S, Baize S, Lerat I, Houhou N, Yazdanpanah Y.

Lancet. 2014 Dec 6;384(9959):2023-4. doi: 10.1016/S0140-6736(14)62226-1. Epub 2014 Nov 19. No abstract available.

PMID:
25467571
28.

Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014.

Kuhn JH, Andersen KG, Baize S, Bào Y, Bavari S, Berthet N, Blinkova O, Brister JR, Clawson AN, Fair J, Gabriel M, Garry RF, Gire SK, Goba A, Gonzalez JP, Günther S, Happi CT, Jahrling PB, Kapetshi J, Kobinger G, Kugelman JR, Leroy EM, Maganga GD, Mbala PK, Moses LM, Muyembe-Tamfum JJ, N'Faly M, Nichol ST, Omilabu SA, Palacios G, Park DJ, Paweska JT, Radoshitzky SR, Rossi CA, Sabeti PC, Schieffelin JS, Schoepp RJ, Sealfon R, Swanepoel R, Towner JS, Wada J, Wauquier N, Yozwiak NL, Formenty P.

Viruses. 2014 Nov 24;6(11):4760-99. doi: 10.3390/v6114760.

29.

Exonuclease domain of the Lassa virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response.

Reynard S, Russier M, Fizet A, Carnec X, Baize S.

J Virol. 2014 Dec;88(23):13923-7. doi: 10.1128/JVI.01923-14. Epub 2014 Sep 24.

30.

The exonuclease domain of Lassa virus nucleoprotein is involved in antigen-presenting-cell-mediated NK cell responses.

Russier M, Reynard S, Carnec X, Baize S.

J Virol. 2014 Dec;88(23):13811-20. doi: 10.1128/JVI.01908-14. Epub 2014 Sep 24.

31.

Emergence of Zaire Ebola virus disease in Guinea.

Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keïta S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traoré A, Kolié M, Malano ER, Heleze E, Bocquin A, Mély S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Günther S.

N Engl J Med. 2014 Oct 9;371(15):1418-25. doi: 10.1056/NEJMoa1404505. Epub 2014 Apr 16.

32.

Production of CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever.

Pannetier D, Reynard S, Russier M, Carnec X, Baize S.

PLoS Negl Trop Dis. 2014 Jan 9;8(1):e2637. doi: 10.1371/journal.pntd.0002637. eCollection 2014.

33.

Immune responses and Lassa virus infection.

Russier M, Pannetier D, Baize S.

Viruses. 2012 Nov 5;4(11):2766-85. doi: 10.3390/v4112766. Review.

34.

NK cells are strongly activated by Lassa and Mopeia virus-infected human macrophages in vitro but do not mediate virus suppression.

Russier M, Reynard S, Tordo N, Baize S.

Eur J Immunol. 2012 Jul;42(7):1822-32. doi: 10.1002/eji.201142099.

35.

Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages.

Carnec X, Baize S, Reynard S, Diancourt L, Caro V, Tordo N, Bouloy M.

J Virol. 2011 Nov;85(22):12093-7. doi: 10.1128/JVI.00429-11. Epub 2011 Aug 31.

36.

Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa.

Leroy EM, Gonzalez JP, Baize S.

Clin Microbiol Infect. 2011 Jul;17(7):964-76. doi: 10.1111/j.1469-0691.2011.03535.x. Review.

37.

[Ebola and Marburg hemorrhagic fever viruses: update on filoviruses].

Leroy E, Baize S, Gonzalez JP.

Med Trop (Mars). 2011 Apr;71(2):111-21. Review. French.

PMID:
21695865
38.

Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Pannetier D, Reynard S, Russier M, Journeaux A, Tordo N, Deubel V, Baize S.

J Virol. 2011 Aug;85(16):8293-306. doi: 10.1128/JVI.02120-10. Epub 2011 Jun 1.

39.

The 2010 Mw 8.8 Maule megathrust earthquake of Central Chile, monitored by GPS.

Vigny C, Socquet A, Peyrat S, Ruegg JC, Métois M, Madariaga R, Morvan S, Lancieri M, Lacassin R, Campos J, Carrizo D, Bejar-Pizarro M, Barrientos S, Armijo R, Aranda C, Valderas-Bermejo MC, Ortega I, Bondoux F, Baize S, Lyon-Caen H, Pavez A, Vilotte JP, Bevis M, Brooks B, Smalley R, Parra H, Baez JC, Blanco M, Cimbaro S, Kendrick E.

Science. 2011 Jun 17;332(6036):1417-21. doi: 10.1126/science.1204132. Epub 2011 Apr 28.

40.

Evidence for Ebola virus superantigen activity.

Leroy EM, Becquart P, Wauquier N, Baize S.

J Virol. 2011 Apr;85(8):4041-2. doi: 10.1128/JVI.00181-11. Epub 2011 Feb 9. No abstract available.

41.

Towards broad protection against Ebolaviruses.

Baize S.

Future Microbiol. 2010 Oct;5(10):1469-73. doi: 10.2217/fmb.10.117.

PMID:
21073307
42.

Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.

Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM.

PLoS Negl Trop Dis. 2010 Oct 5;4(10). pii: e837. doi: 10.1371/journal.pntd.0000837.

43.

Land-level changes produced by the Mw 8.8 2010 Chilean earthquake.

Farías M, Vargas G, Tassara A, Carretier S, Baize S, Melnick D, Bataille K.

Science. 2010 Aug 20;329(5994):916. doi: 10.1126/science.1192094. Epub 2010 Jul 29.

44.

Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.

Baize S, Marianneau P, Loth P, Reynard S, Journeaux A, Chevallier M, Tordo N, Deubel V, Contamin H.

J Virol. 2009 Jun;83(11):5890-903. doi: 10.1128/JVI.01948-08. Epub 2009 Mar 18.

45.

Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection.

Georges-Courbot MC, Contamin H, Faure C, Loth P, Baize S, Leyssen P, Neyts J, Deubel V.

Antimicrob Agents Chemother. 2006 May;50(5):1768-72.

46.

Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages.

Baize S, Pannetier D, Faure C, Marianneau P, Marendat I, Georges-Courbot MC, Deubel V.

Microbes Infect. 2006 Apr;8(5):1194-202. Epub 2006 Mar 20.

PMID:
16621649
47.

A single shot against Ebola and Marburg virus.

Baize S.

Nat Med. 2005 Jul;11(7):720-1. No abstract available.

PMID:
16015361
48.

[Epidemics of Ebola haemorrhagic fever in Gabon (1994-2002). Epidemiologic aspects and considerations on control measures].

Milleliri JM, Tévi-Benissan C, Baize S, Leroy E, Georges-Courbot MC.

Bull Soc Pathol Exot. 2004 Aug;97(3):199-205. French.

PMID:
15462203
49.

Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection.

Pannetier D, Faure C, Georges-Courbot MC, Deubel V, Baize S.

J Virol. 2004 Oct;78(19):10516-24.

50.

Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells.

Baize S, Kaplon J, Faure C, Pannetier D, Georges-Courbot MC, Deubel V.

J Immunol. 2004 Mar 1;172(5):2861-9.

Supplemental Content

Support Center